Literature DB >> 19962475

Effectiveness and safety of total endoscopic left internal mammary artery bypass graft to the left anterior descending artery.

Johannes Bonatti1, Thomas Schachner, Nikolaos Bonaros, Armin Oehlinger, Dominik Wiedemann, Elisabeth Ruetzler, Felix Weidinger, Christian Kolbitsch, Gudrun Feuchtner, David Zimrin, Guy Friedrich, Otmar Pachinger, Guenther Laufer.   

Abstract

Totally endoscopic coronary artery bypass grafting (CABG) has become a feasible option using robotic technology and remote access perfusion techniques. The aim of this study was to determine the progression of the procedure's performance in the currently largest single-center series of arrested-heart totally endoscopic CABG. From 2001 to 2007, arrested-heart totally endoscopic CABG was performed in 100 patients (median age 59 years, range 46 to 70; 81 men, 19 women). All patients received left internal mammary artery grafts to the left anterior descending artery using the da Vinci Surgical System. Remote-access femoral perfusion and aortic balloon endo-occlusion were used in all patients. The series was divided into 4 phases: phase 1 (patients 1 to 25), phase 2 (patients 26 to 50), phase 3 (patients 51 to 75), and phase 4 (patients 76 to 100). The conversion rates to larger thoracic incisions were 7 of 25 (28%) in phase 1, 2 of 25 (8%) in phase 2, 1 of 25 (4%) in phase 3, and 1 of 25 (4%) in phase 4 (p = 0.018). Operative times and hospital stays decreased significantly with each subsequent phase, and clinical outcome showed corresponding improvements. There was no perioperative mortality. For the whole patient series, 5-year postoperative survival, freedom from angina, and freedom from major adverse cardiac and cerebral events were 100%, 91%, and 89%, respectively. In conclusion, after an initial steep learning curve, completely endoscopic left internal mammary artery-to-left anterior descending CABG can be performed safely, with low conversion rates. The learning curve for operative times and improvements in clinical outcome continued even at 100 procedures.

Entities:  

Mesh:

Year:  2009        PMID: 19962475     DOI: 10.1016/j.amjcard.2009.07.051

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Advances in surgical treatment of acute and chronic coronary artery disease.

Authors:  William E Cohn
Journal:  Tex Heart Inst J       Date:  2010

2.  Endoscopic harvesting of the left internal mammary artery.

Authors:  Tomasz Hrapkowicz; Gianluigi Bisleri
Journal:  Ann Cardiothorac Surg       Date:  2013-07

Review 3.  Robotically assisted totally endoscopic coronary artery bypass surgery.

Authors:  Leonardo Secchin Canale; Stephanie Mick; Tomislav Mihaljevic; Ravi Nair; Johannes Bonatti
Journal:  J Thorac Dis       Date:  2013-11       Impact factor: 2.895

4.  Robot-assisted coronary artery bypass surgery: a systematic review and meta-analysis of comparative studies.

Authors:  Fadi Hammal; Fernanda Nagase; Devidas Menon; Imtiaz Ali; Jeevan Nagendran; Tania Stafinski
Journal:  Can J Surg       Date:  2020 Nov-Dec       Impact factor: 2.089

5.  Systematic review of robotic-assisted, totally endoscopic coronary artery bypass grafting.

Authors:  Michael Seco; J James B Edelman; Tristan D Yan; Michael K Wilson; Paul G Bannon; Michael P Vallely
Journal:  Ann Cardiothorac Surg       Date:  2013-07

6.  Review of Contemporary Techniques for Minimally Invasive Coronary Revascularization.

Authors:  Ali Fatehi Hassanabad; Jimmy Kang; Andrew Maitland; Corey Adams; William D T Kent
Journal:  Innovations (Phila)       Date:  2021-06-03

7.  Minimally invasive surgical techniques in the era of hybrid coronary revascularization: additional benefits for the elderly patients?

Authors:  Antonio Nenna; Mario Lusini; Salvatore Matteo Greco; Elvio Covino; Massimo Chello
Journal:  J Geriatr Cardiol       Date:  2016-10       Impact factor: 3.327

8.  Robotic totally endoscopic coronary artery bypass grafting: It's now or never!

Authors:  Husam H Balkhy
Journal:  JTCVS Tech       Date:  2021-04-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.